Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity

 
• By Jessica Merrill

The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.

reputation management concept
COVID-19 presents a rare chance for pharma to improve its rating by the public • Source: Shutterstock

More from COVID-19

More from Scrip